Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.

Eva Herweijer; Amy Leval; Alexander Ploner; Sandra Eloranta; Julia Fridman Simard; Joakim Dillner; Eva Netterlid; Pär Sparén; Lisen Arnheim-Dahlström

doi:10.1001/jama.2014.95

Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.

Eva Herweijer, Amy Leval, Alexander Ploner, Sandra Eloranta, Julia Fridman Simard, Joakim Dillner, Eva Netterlid, Pär Sparén, Lisen Arnheim-Dahlström

Research output: Contribution to journal › Article › peer-review

Abstract

Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.

Original language	English
Pages (from-to)	597-603
Journal	JAMA: The Journal of the American Medical Association
Volume	311
Issue number	6
DOIs	https://doi.org/10.1001/jama.2014.95
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Subject classification (UKÄ)

Occupational Health and Environmental Health
Dermatology and Venereal Diseases

Free keywords

Condylomata Acuminata: epidemiology
Condylomata Acuminata: prevention & control
Papillomavirus Infections: prevention & control
Papillomavirus Vaccines: administration & dosage
Registries: statistics & numerical data
Sweden: epidemiology
Uterine Cervical Neoplasms: prevention & control
Vaccination: statistics & numerical data

Access to Document

10.1001/jama.2014.95

http://www.ncbi.nlm.nih.gov/pubmed/24519299?dopt=Abstract

Cite this

@article{dc33635d238f466eb344255141fe2306,

title = "Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.",

abstract = "Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.",

keywords = "Condylomata Acuminata: epidemiology, Condylomata Acuminata: prevention \& control, Papillomavirus Infections: prevention \& control, Papillomavirus Vaccines: administration \& dosage, Registries: statistics \& numerical data, Sweden: epidemiology, Uterine Cervical Neoplasms: prevention \& control, Vaccination: statistics \& numerical data",

author = "Eva Herweijer and Amy Leval and Alexander Ploner and Sandra Eloranta and Simard, \{Julia Fridman\} and Joakim Dillner and Eva Netterlid and P{\"a}r Spar{\'e}n and Lisen Arnheim-Dahlstr{\"o}m",

year = "2014",

doi = "10.1001/jama.2014.95",

language = "English",

volume = "311",

pages = "597--603",

journal = "JAMA: The Journal of the American Medical Association",

issn = "1538-3598",

publisher = "American Medical Association",

number = "6",

}

TY - JOUR

T1 - Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.

AU - Herweijer, Eva

AU - Leval, Amy

AU - Ploner, Alexander

AU - Eloranta, Sandra

AU - Simard, Julia Fridman

AU - Dillner, Joakim

AU - Netterlid, Eva

AU - Sparén, Pär

AU - Arnheim-Dahlström, Lisen

PY - 2014

Y1 - 2014

N2 - Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.

AB - Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.

KW - Condylomata Acuminata: epidemiology

KW - Condylomata Acuminata: prevention & control

KW - Papillomavirus Infections: prevention & control

KW - Papillomavirus Vaccines: administration & dosage

KW - Registries: statistics & numerical data

KW - Sweden: epidemiology

KW - Uterine Cervical Neoplasms: prevention & control

KW - Vaccination: statistics & numerical data

UR - https://www.scopus.com/pages/publications/84893666624

U2 - 10.1001/jama.2014.95

DO - 10.1001/jama.2014.95

M3 - Article

C2 - 24519299

SN - 1538-3598

VL - 311

SP - 597

EP - 603

JO - JAMA: The Journal of the American Medical Association

JF - JAMA: The Journal of the American Medical Association

IS - 6

ER -

Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.

Abstract

UN SDGs

Subject classification (UKÄ)

Free keywords

Access to Document

Other files and links

Fingerprint

Cite this